Engineering a new way to study hepatitis C - Part IV (b) Tavistock group

Vatic Note:  Again we see MIT involved along with the Rockefeller University keeping in mind the many decades of close relationship between rockefeller and the Tavistock Group and their psychological work in Human relations.  Is this the new AIDS pandemic?   Suspicion is prevelant due to the Cheney's New American think tank's  "Pax Americana" paper that began all that we see.   In that paper was a section that stated "....using bioweapons, by genotype, for political reasons".    That alone was cause for great concern and with no trust anymore in anything to do with international governance, its easy to made the connection of this to the robber barons stated purpose and funding programs to eugenics and depopulation.   Keep that in mind.   Controlling how we react to all of this is assigned to the tavistock group to deal with and they do through their affiliates here in the states like MIT and other think tanks and research facilities and government agencies such as the CIA.   Part V will tie all this together.
Part I
Part II
Part III
Part IV  &  Part IV (a)

Title:   Engineering a new way to study hepatitis C

Jen Hirsch - MIT News Office
January 25, 2010
http://web.mit.edu/press/2010/hepatitis-c.html

CAMBRIDGE, Mass. — Researchers at MIT and Rockefeller University have successfully grown hepatitis C virus in otherwise healthy liver cells in the laboratory, an advance that could allow scientists to develop and test new treatments for the disease.

About 200 million people worldwide are infected with hepatitis C, which can lead to liver failure or cancer, and existing drugs are not always effective. To develop better treatments, researchers need to test them in laboratory experiments in liver cells, but it has been difficult to create a suitable tissue model because healthy liver cells tend to lose their liver functions when removed from the body.

Previously, researchers have been able to induce cancerous liver cells to survive and reproduce outside the body, but those cells are not sufficient for studying hepatitis C because their responses to infection are different from those of normal liver cells.

Now, Sangeeta Bhatia, professor in the Harvard-MIT Division of Health Sciences and Technology, in collaboration with Charles Rice of the Rockefeller University, has developed a way to maintain liver cells for four to six weeks by precisely arranging them on a specially patterned plate. The cells can be infected with hepatitis C for two to three weeks, giving researchers the chance to study the cells’ responses to different drugs.

The new model, described in next week’s issue of the Proceedings of the National Academy of Sciences, could allow researchers to test the effectiveness of various combinations of drugs, including interferon, a common current treatment, and experimental antibodies that may block the virus from entering cells.

How they did it: The researchers used healthy liver cells that had been cryogenically preserved and grew them on special plates with micropatterns that direct the cells where to grow. The liver cells were strategically interspersed with other cells called fibroblasts that support the growth of liver tissue.

“If you just put cells on a surface in an unorganized way, they lose their function very quickly,” says Bhatia. “If you specify which cells sit next to each other, you can extend the lifetime of the cells and help them maintain their function.”

Next steps: The current system may already be suitable to screen drugs against the strain of hepatitis C used in this work; however, this strain, which was derived from a Japanese patient with fulminant hepatitis, is the only strain ever successfully grown in a laboratory environment. The researchers hope to modify the system so they can grow additional strains, such as those more common in North America, which would allow for more thorough drug testing.

Source: “Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures,” Alexander Ploss, Salman Khetani, et al. Proceedings of the National Academy of Sciences, week of Jan. 25, 2010.

Funding: Greenberg Medical Research Institute, Ellison Medical Foundation, Starr Foundation, Ronald A. Shellow Memorial Fund, Richard Salomon Family Foundation, Howard Hughes Medical Institute, and the National Institutes of Health through the NIH Roadmap for Medical Research, Grant 1 R01 DK085713-01.

---

The article is reproduced in accordance with Section 107 of title 17 of the Copyright Law of the United States relating to fair-use and is for the purposes of criticism, comment, news reporting, teaching, scholarship, and research.